TRRI — Alzex Neuropharma Share Price
Last trade - 00:00- $0.15m
- $0.21m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 575.48 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1162.14% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.01 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alzex Neuropharma Inc., formerly Trinity Resources Inc., is a biopharmaceutical company. The Company is engaged in research and development targeting treatments of brain diseases. It is also focused on chemical development of its new drugs dedicated to the symptomatic treatment of Alzheimer’s Disease but can be applied to other neurological diseases due to its platform technology.
Directors
- Last Annual
- December 31st, 2012
- Last Interim
- September 30th, 2013
- Incorporated
- March 12th, 1971
- Public Since
- July 11th, 2001
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,505,268
- Address
- 2850 West Horizon Ridge, Suite 200, HENDERSON, 89052
- Web
- https://trinresinc.com/
- Phone
- +1 3104350435
- Auditors
Upcoming Events for TRRI
Similar to TRRI
1399 Internet Technology Application
Pink Sheets on Nasdaq
3D Pioneer Systems
Pink Sheets on Nasdaq
9 Meters Biopharma
Pink Sheets on Nasdaq
Absolute Health and Fitness
Pink Sheets on Nasdaq
ACC Aviation Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 23:49 UTC, shares in Alzex Neuropharma are trading at $0.20. This share price information is delayed by 15 minutes.
Shares in Alzex Neuropharma last closed at $0.20 and the price had moved by +37.1% over the past 365 days. In terms of relative price strength the Alzex Neuropharma share price has outperformed the S&P500 Index by +15.07% over the past year.
There is no consensus recommendation for this security.
Alzex Neuropharma does not currently pay a dividend.
Alzex Neuropharma does not currently pay a dividend.
Alzex Neuropharma does not currently pay a dividend.
To buy shares in Alzex Neuropharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.20, shares in Alzex Neuropharma had a market capitalisation of $0.30m.
Here are the trading details for Alzex Neuropharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: TRRI
Based on an overall assessment of its quality, value and momentum Alzex Neuropharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alzex Neuropharma. Over the past six months, its share price has underperformed the S&P500 Index by -9.99%.
As of the last closing price of $0.20, shares in Alzex Neuropharma were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alzex Neuropharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alzex Neuropharma's management team is headed by:
- Robert Rosner - CEO